Who are KI1106 4g, QD's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SCTB14, SHR-1314, mini CYVE, without 3 maintenance courses, RNF.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ki1106-4g-qd.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

KI1106 4g, QD — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

KI1106 4g, QD (KI1106 4g, QD) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD47/SIRPα inhibitor. Area: Oncology.

phase 3 CD47/SIRPα inhibitor CD47/SIRPα axis Oncology Small molecule Live · refreshed every 30 min

Target snapshot

KI1106 4g, QD (KI1106 4g, QD) — Kuhnil Pharmaceutical Co., Ltd.. KI1106 is a small molecule targeting the CD47/SIRPα axis.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
KI1106 4g, QD TARGET	KI1106 4g, QD	Kuhnil Pharmaceutical Co., Ltd.	phase 3	CD47/SIRPα inhibitor	CD47/SIRPα axis
SCTB14	SCTB14	Sinocelltech Ltd.	phase 3	CD47/SIRPα axis inhibitor	CD47/SIRPα axis
SHR-1314	SHR-1314	Jiangsu HengRui Medicine Co., Ltd.	phase 3	CD47/SIRPα inhibitor	CD47/SIRPα axis
mini CYVE, without 3 maintenance courses	mini CYVE, without 3 maintenance courses	Gustave Roussy, Cancer Campus, Grand Paris	phase 3	CD47/SIRPα inhibitor	CD47
RNF	RNF	Merck KGaA, Darmstadt, Germany	phase 3	CD47/SIRPα inhibitor	CD47

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD47/SIRPα inhibitor class)

BicycleTx Limited · 1 drug in this class
Gustave Roussy, Cancer Campus, Grand Paris · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Kuhnil Pharmaceutical Co., Ltd. · 1 drug in this class
Merck KGaA, Darmstadt, Germany · 1 drug in this class
Pharmicell Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KI1106 4g, QD — Competitive Intelligence Brief. https://druglandscape.com/ci/ki1106-4g-qd. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab